Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522476 | 0.93 | CNR2 (0.47) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522330 | 0.91 | MAPK1 (0.44) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522192 | 0.91 | MAPK1 (0.46) | MAPK1HSD17B10CNR2CNR1TP53 | |
| SCHEMBL1523088 | 0.91 | MAPK1 (0.54) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522693 | 0.91 | MAPK1 (0.45) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522430 | 0.91 | MAPK1 (0.42) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1523058 | 0.90 | CNR2 (0.43) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL6757879 | 0.90 | CNR2 (0.43) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522598 | 0.89 | MAPK1 (0.41) | MAPK1HSD17B10CNR2CNR1CYP2C9 | |
| SCHEMBL1522591 | 0.89 | MAPT (0.47) | MAPK1HSD17B10CNR2CNR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | claimed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | claimed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | claimed |
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1560827-B1 | ANTI-INFECTIVE AGENTS | ABBOTT LAB (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097492-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885CNR2 4494/4885 |
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885CNR2 4494/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | MAPK1 739/4885HSD17B10 1422/4885CNR2 4140/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | MAPK1 2328/4885HSD17B10 1335/4885CNR2 4150/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | MAPK1 1456/4885HSD17B10 1232/4885CNR2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.